Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 09 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Vitamin D is associated with reduced risk of C. difficile in IBD

Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases, reports this month's issue of the Alimentary Pharmacology & Therapeutics.

News image

Patients with inflammatory bowel diseases (IBD) have an increased risk of Clostridium difficile infection (CDI).

Cathelicidins are anti-microbial peptides that attenuate colitis and inhibit the effect of clostridial toxins.

Plasma calcifediol [25(OH)D] stimulates production of cathelicidins.

Dr Ananthakrishnan and colleagues from Massachussetts, USA examined the association between plasma 25(OH)D and CDI in patients with IBD.

From a multi-institutional IBD cohort, the research team identified patients with at least one measured plasma 25(OH)D.

Each 1 ng/mL increase in plasma 25(OH)D was associated with a 4% reduction in risk of CDI
Alimentary Pharmacology & Therapeutics

The team's primary outcome was development of CDI.

Multivariate logistic regression models adjusting for potential confounders were used to identify independent effect of plasma 25(OH)D on risk of CDI.

The team studied 3188 IBD patients of whom 35 patients developed CDI.

The research team observed that patients with CDI-IBD were older and had greater co-morbidity.

The mean plasma 25(OH)D level was significantly lower in patients who developed CDI compared to non-CDI-IBD patients.

On further analysis, the team observed that each 1 ng/mL increase in plasma 25(OH)D was associated with a 4% reduction in risk of CDI.

Compared to individuals with vitamin D >20 ng/mL, patients with levels <20 ng/mL were more likely to develop CDI.

The mean plasma 25(OH)D in patients with CDI who subsequently died was significantly lower compared to those who were alive at the end of follow-up.

Dr Ananthakrishnan's team concludes, "Higher plasma calcifediol [25(OH)D] is associated with reduced risk of C. difficile infection in patients with IBD."

"Further studies of therapeutic supplementation of vitamin D in patients with inflammatory bowel disease and C. difficile infection may be warranted."

Aliment Pharmacol Ther 2014: 39(10): 1136–1142
06 May 2014

Go to top of page Email this page Email this page to a colleague

 09 February 2016 
Eosinophilic esophagitis and parental allergies
 09 February 2016 
Cancer-specific prognosis in octogenarians with colorectal cancer
 09 February 2016 
Bowel preparation for colonoscopy screening
 08 February 2016 
Immunity in the human gut
 08 February 2016 
Cancelled colonoscopy appointments
 08 February 2016 
Cognitive function in Crohn's disease
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 05 February 2016 
Methotrexate and remission in ulcerative colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 01 February 2016 
Depressive symptoms in IBD 
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's
 15 January 2016 
Alcohol- and HCV-related hepatocellular carcinoma
 15 January 2016 
Recurrent colonic diverticulitis
 15 January 2016 
Colonic diverticula and colorectal cancer risk
 14 January 2016 
Risk stratification of incidentally discovered gallstones
 14 January 2016 
Treatment of refractory cholestatic pruritus
 14 January 2016 
Colonic diverticula and colorectal cancer risk 
 13 January 2016 
C-section delivery and IBD risk
 13 January 2016 
Primary biliary cholangitis treatment with incomplete UDCA response
 13 January 2016 
Colon cancer screening rates 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us